Sarah Cannon Research Institute’s Post

NEW from #ASCO2024 | Evaluating JZP898, an IFN-α and #pembrolizumab in advanced #solidtumors 🎥 🇺🇸 Meredith McKean, MD, MPH, Sarah Cannon Research Institute, shares findings from a Phase I, first-in-human study (NCT06108050) of JZP898, a conditionally activated prodrug of interferon alpha (IFN-α), alone or combined with #pembrolizumab in patients with advanced or #metastatic #solidtumors 🌟 The study aims to determine the maximum tolerated dose, safety, tolerability, #pharmacokinetics, and preliminary #antitumor activity 🌟 The combination is designed to enhance antitumor effects while minimizing systemic toxicity 🌟 Primary endpoints include dose-limiting toxicities and objective response rate, with secondary endpoints covering pharmacokinetics and overall survival Learn more 👉 https://lnkd.in/gzjRxJY7 #VJOncology #Oncologynews

We were thrilled today to present at the American Society of Clinical Oncology (ASCO) Annual Meeting. Two poster presentations spotlighted clinical trial data for Black Diamond’s #EGFR inhibitor BDTX-1535 in patients with recurrent #glioblastoma (GBM). These data were from a Phase 1 dose-escalation trial and a “window of opportunity” (Phase 0/1 “Trigger”) Investigator Sponsored Trial at the Ivy Brain Tumor Center.   Results demonstrated a favorable safety and tolerability profile and encouraging anti-tumor activity and duration of treatment. BDTX-1535 was also shown to achieve clinically meaningful drug levels in brain tumor tissue. Read more: https://lnkd.in/epsPKu_c View the posters here: https://lnkd.in/e3JeikQf   #ASCO2024 #GBM #oncology #biotech #healthcare #innovation

Choosing the RIGHT model for your preclinical Immuno-Oncology and Oncology studies is crucial to accelerating your research. Download our Quick Guide comparing Syngeneic & Humanized Mouse Models and learn how to weigh the benefits and challenges you face when working with these models for oncology research. Learn More: https://hubs.li/Q02dkSqj0 #OncologyResearch #CancerResearch #ImmunoOncology #Humanized #Syngeneic

🚨 New Videos Alert: Groundbreaking Insights into PRRT for Neuroendocrine Tumors (NET)  We’ve uploaded two expert-led discussions on www.AccrediMix.be, shedding light on the latest advances in Peptide Receptor Radionuclide Therapy (PRRT) for NET patients. Moderated by Prof Chris Verslype, with insights from Prof Timon Vandamme and Prof Christophe Deroose, these videos dive deep into the most recent clinical findings and future innovations. 📽️ Part 1: Explore the NETTER-1 trial and how PRRT is transforming care for somatostatin receptor-positive tumors. 📽️ Part 2: Discover advanced imaging techniques and learn about the future of alpha-emitter therapies like Actinium-225. Register or log in at accredimix.be to access this essential content and stay at the forefront of oncology care! Stay at the forefront of oncology with these essential resources.  #oncology #NETs #PRRT #cancertreatment #AccrediMix #medicalinnovation With the educational support of Ipsen. *This educational content is intended for healthcare professionals.

Today CStone announced the presentation of long-term survival data for sugemalimab in combination with platinum-based chemotherapy from the GEMSTONE-302 study at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting. Four-year follow-up data continue to demonstrate significant benefit in progression-free survival and overall survival for sugemalimab plus platinum-based chemotherapy compared to placebo plus platinum-based chemotherapy. The four-year survival rate is 32.1% vs 17.3%. Sustained and consistent benefits are observed across different histological subtypes and PD-L1 expression levels. Read more here: https://lnkd.in/g6P3zbbh

Small Contribution in the world of oncology care has just been published! newly released book chapter titled "Somatic Mutations: Pharmacogenomic in Oncology Care." Dive into the world of cutting-edge research and explore the intricate relationship between somatic mutations and pharmacogenomics. Our chapter delves into the latest advancements that promise to revolutionize oncology care. #OncologyCare #ResearchMilestone #Pharmacogenomics #SomaticMutations #MedicalBreakthroughshttps https://lnkd.in/gp4HAiQa

Intriguing pre-clinical data suggests that inhibiting complement improves the efficacy of immune checkpoint inhibitors, which are a mainstay of oncology treatment. Several clinical trials are already evaluating the combination of investigational inhibitors of different complement factors with PD-1 inhibitors in several solid tumors. Central to evaluating this novel treatment approach will be the ability to deliver accurate and timely complement analysis. If this can be done, it is hoped these diagnostic advances will help to enrich clinical trial populations and ultimately get new treatments to patients more quickly. Find out how Kypha’s complement diagnostic technology is designed to measure complement factors such as C3 and C5a in real-time. Visit https://lnkd.in/eU8c3Srk #immunediagnostics #complement #checkpointinhibitors #precisionimmunemonitoring

Endpoints in malignant hematology studies differ significantly from those used for solid tumors. In this white paper, Christopher Morley and Sari Heitner Enschede, MD consider the most effective investigational agents for blood-based cancers. Download now. https://bit.ly/49jyTXh #oncology #hematology #biotech #ClinicalTrials #diversity

Encouraging activity in CCNE activated ovarian and endometrial cancers

In his abstract presentation at the 2024 annual meeting of the American Society of Clinical Oncology (ASCO), University of California, Irvine hematology/oncology fellow Omid Yazdanpanah, MD shed light on the critical yet often overlooked aspect of patient preferences in managing metastatic renal cell carcinoma (mRCC). The study addresses the evolving landscape of first-line therapies for clear cell mRCC, which now includes combinations of tyrosine kinase inhibitors (TKIs) with immuno-oncology (IO) agents or dual IO therapies. While oncologists traditionally rely on guidelines and personal experience to guide treatment decisions, understanding patient preferences is crucial for personalized care. Yazdanpanah's research, filling a significant gap in existing literature, investigates how patients perceive and prioritize treatment options compared to healthcare providers. By exploring these perspectives, the study aims to enhance the alignment between patient-centered care and clinical decision making in mRCC management.